LtaS-IN-1 NEW
| Price | $31 | $73 | $107 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-21 |
Product Details
| Product Name: LtaS-IN-1 | CAS No.: 877950-01-1 |
| Purity: 93.44% | Supply Ability: 10g |
| Release date: 2026/04/21 |
Product Introduction
Bioactivity
| Name | LtaS-IN-1 |
| Description | LtaS-IN-1 is an effective inhibitor of Lipoteichoic acid synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 is against Enterococcus spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 inhibits strain E1630 and E1590 with MIC values of 0.5 μg/mL. |
| In vitro | LtaS-IN-1 (20 μM) combines with either ampicillin (20 μg/mL), gentamicin (10 μg/mL), linezolid (5 μg/mL), daptomycin (10 μg/mL+50 μg/mL calcium chloride) or vancomycin (20 μg/mL) can inhibit strains E7128 and E7130 growth by 97-100%, while LtaS-IN-1 alone only gives 73% (strain E7128) and 8% (strain E7130) of growth inhibition, respectively. LtaS-IN-1 (0-100 μM) inhibits strain E745 growth as a concentration-dependent manner. LtaS-IN-1 (10 μM) leads to a 60% reduction in the final OD600 for this strain. Meanwhile, LtaS-IN-1 does not affect E. faecium growth in control group[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 120 mg/mL (280.76 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 3.3 mg/mL (7.72 mM), Sonication is recommended. |
| Keywords | strain E1630 | strain E1590 | multidrug-resistant | MDR | LtaS-IN-1 | LtaSIN1 | LtaS IN 1 | Inhibitor | inhibit | E. faecium | Bacterial | anti-bacterial |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Anti-Bacterial Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
| $95.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-26 | |
| $2.00 |
VIP2Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2026-04-17 | |
| $31.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY